Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
How AI Innovation Is Widening The Digital Health Divide
OpenAI unveiled ChatGPT Health, a generative AI tool that aggregates personal health data across portals. Early adopters like tech‑entrepreneur Sergei Polevikov reported hallucinated records and administrative friction, highlighting usability gaps. Interviews in Mobile, Alabama reveal that many low‑income users already rely on voice assistants yet remain unaware that they are AI‑driven, underscoring a broader digital‑literacy divide. Philanthropic initiatives such as Humanity AI are mobilizing $500 million to steer AI development toward inclusive, people‑centered solutions.
Implantable Bacteria Can Now Be Safely Contained, Clearing a Major Hurdle for Fighting Infection and Cancer
Harvard researchers have engineered a polyvinyl alcohol (PVA) hydrogel scaffold that securely contains therapeutic bacteria for up to six months, preventing escape while allowing drug‑release functions. The scaffold’s stiffness and toughness give it a ten‑fold higher fatigue threshold than prior...
Endoscopic Sleeve Gastroplasty Outperforms Oral Semaglutide in Short-Term Weight Loss
A comparative real‑world study of 150 obese adults presented at ESGE Days 2026 found that endoscopic sleeve gastroplasty (ESG) produced significantly greater short‑term weight loss than 14 mg oral semaglutide. At six months, ESG patients lost an average 12.7 % of body weight...
Trump Administration Exempts Doctors From Work Visa Freeze
The U.S. Department of Homeland Security has lifted the freeze on processing existing H‑1B visas for foreign‑born physicians, allowing them to begin or continue work in American hospitals. The exemption comes after pressure from medical societies such as the ACC...
Trials Support Thrombectomy in Very Late Time Windows, Milder Strokes
Two randomized trials presented at the European Stroke Organisation Conference 2026 broaden the therapeutic horizon for acute ischemic stroke. LATE‑MT demonstrated that mechanical thrombectomy up to 72 hours after symptom onset improves functional outcomes, though it carries higher rates of death...
Regenxbio's RGX-202 Hits Phase 3 Primary Endpoint, Eyes FDA Filing
Regenxbio announced that its RGX-202 gene therapy met the primary endpoint of its pivotal Phase 3 trial, with 28 of 30 patients achieving at least 10% normal dystrophin levels and an average expression of 71.1%. The company says the data...
Dexcom Unveils G8 CGM, a 50% Smaller Sensor Set for 2027 Launch
Dexcom introduced its next‑generation G8 continuous glucose monitor at an Investor Day event, touting a sensor that is 50% smaller than the current G7 and built on a new silicon‑chip platform. The company said regulatory filings are slated for next...
Thousands of Reprocessed EP Catheters Recalled
Stryker Sustainability Solutions, the reprocessing arm of Stryker, announced a Class II recall of more than 8,000 reprocessed electrophysiology (EP) catheters after discovering incomplete seals caused by a process‑control lapse. The recall spans multiple device models from manufacturers such as BARD,...
Longitude Health Appoints Ian Spier as CFO to Drive Capital Strategy
Longitude Health announced Ian Spier as its new chief financial officer. The former Novant Health senior vice president brings roughly $15 billion in M&A and $8 billion in capital‑markets expertise, positioning the collaborative to expand its system‑designed utilities and capital planning.
HealthSplash Founder Convicted in $1 Billion Medicare Fraud Scheme
A federal jury in Miami convicted HealthSplash founder Brett Blackman of orchestrating a scheme that billed Medicare more than $1 billion for unnecessary medical equipment. The verdict underscores the Justice Department’s intensified focus on large‑scale health‑care fraud targeting seniors.
Elliott Investment Management Takes Stake in Dexcom, Secures Two Board Seats
Elliott Investment Management has acquired an undisclosed stake in glucose‑monitor maker Dexcom and negotiated a settlement that adds two independent directors to the board. The move, announced by CEO Jake Leach, signals activist pressure to sharpen the company’s operational and...
ECO 2026: Indirect Comparison Favours Wegovy Pill over Foundayo
At the 33rd European Congress on Obesity, Novo Nordisk presented a post‑hoc indirect comparison of oral semaglutide (Wegovy pill) versus orforglipron (Foundayo). Using simulated treatment comparison and matching‑adjusted indirect methods, the analysis showed Wegovy achieved roughly 3 percentage‑points greater weight...
Gold Nanoparticle Platform Shows 99% Tumor Regression in Preclinical Study
Researchers at the National University of Singapore have unveiled a high‑throughput DNA‑barcoding method that identified a folic‑acid‑modified cubic gold nanoparticle capable of delivering RNA therapy and photothermal treatment directly to cancer‑cell mitochondria, producing 99% tumor regression in animal models. The...
Patient, Doctor, Health System Affect Glaucoma Drop Compliance
A UK‑based study published in Optometry and Vision Science examined glaucoma drop adherence among 13 patients and 13 eye‑care practitioners. Patients reported missed doses due to routine disruptions, prescription delays, and difficulty instilling drops, while clinicians cited time pressures, staffing...
CREAL Inc Posts Full-Year Net Profit Rise to ¥1.94 Bn Despite 9.6% Revenue Drop
CREAL Inc announced a full‑year net profit of ¥1.938 billion, a 44% increase over the prior year, even as revenue slipped 9.6% to ¥37.795 billion. The earnings boost reflects stronger margins on its commercialized pipeline, signaling resilience amid a softer top line.
Medical Apology Laws Don’t Reduce Malpractice Lawsuits
Medical apology statutes, now in 39 states, DC and Guam, were intended to lower malpractice risk by letting clinicians express regret without legal penalty. Recent studies, however, show that apologies alone do not curb lawsuits and can even increase claims...
Sonomind Raises €20M for Ultrasound Neuromodulation Technology
Sonomind SAS announced a €20 million (approximately $23 million) Series A round to advance its ultrasound‑based neuromodulation platform for depression. The capital will fund clinical trials of a non‑invasive device that employs a custom acoustic lens to focus sound waves on deep brain...
Health Authorities Order Halt to Use of Medical Devices Tied to Patient’s Death
Hong Kong health authorities have ordered an immediate stop to a batch of blood‑pressure monitoring sets after an improperly sealed catheter connector was linked to the death of a 75‑year‑old patient undergoing balloon angioplasty. The Department of Health instructed the...
Psilocybin Offers Fast-Acting Alternative to Traditional Antidepressants
A phase‑2, double‑blind trial in Sweden found that a single 25 mg dose of psilocybin produced rapid antidepressant effects, cutting MADRS scores by an average of 9.7 points within eight days versus 2.4 points for an active placebo. The benefit persisted...
Carl Zeiss Says Restructuring Could Affect up to 1,000 Jobs
Carl Zeiss Meditec announced a restructuring that could cut up to 1,000 jobs worldwide over the next three years. The move follows a 5.7% drop in first‑half revenue to €991 million (about $1.09 billion) and a fall in adjusted EBITDA to €60.5 million...
Part I: How Geotagged EVV Check-In Data Can Get Wired Into Medicaid and Medicare Managed Care Claim Edits to Reject...
The episode dissects the persistent fraud problem in home health agencies, highlighting how the recent CMS nationwide enrollment moratorium aims to curb new bad actors but does nothing for the roughly 11 agencies already in the system. It explains that...
Candel Reports Prostate Cancer Drug's Long-Term Data Ahead of FDA Filing
Candel Therapeutics released long‑term follow‑up results for its investigational prostate cancer therapy, showing durable efficacy and a favorable safety profile. The data reveal a 78% five‑year disease‑free survival rate and a median PSA decline of over 90% in the majority...
IPF Linked to Higher Mortality, Costs in Hospitalized Patients With CDI
A retrospective analysis of 1.48 million Clostridium difficile infection (CDI) hospitalizations identified 1,600 patients with idiopathic pulmonary fibrosis (IPF). After propensity‑score matching, IPF patients experienced double the in‑hospital mortality (12.2% vs 6.2%) and stayed nearly four days longer. Hospital charges averaged...
Timing of PPV a Biomarker for Vision Gains in DME
A multicenter study presented at Retina World Congress found that small‑gauge pars plana vitrectomy (PPV) performed within 12 months of diabetic macular edema (DME) diagnosis yields significant visual acuity gains and anatomical improvement over 24 months. Timing emerged as a...
Independent Physicians Are Missing From Health Care Policy
A new federal Health Care Advisory Committee will shape Medicare, Medicaid and other programs, but it lacks any independent, private‑practice physicians. Independent doctors—about 250,000, or roughly one‑quarter of U.S. physicians—manage chronic illness daily and face steep administrative and payment challenges....
PFA Has Been a Game-Changer for Heart Patients—But There Are Still Risks
Pulsed field ablation (PFA) is reshaping atrial fibrillation treatment by using electrical fields instead of heat, delivering a markedly safer profile than radiofrequency or cryoablation. Clinicians report near‑zero phrenic nerve and esophageal injury, accelerating adoption of multiple FDA‑cleared catheters such...
9amHealth Raises $26M for Virtual Specialty Care Platform and More Funding News
9amHealth secured $26 million Series B funding led by Define Ventures, adding founder Lynne O'Keefe to its board. Optura raised $17.5 million in a Series A round, bringing total capital to $25 million, with Salesforce Ventures spearheading the effort to expand AI and large‑language‑model capabilities....
More Hospitals Receive 5 Stars in the Hospital Star Ratings Program
The Centers for Medicare & Medicaid Services (CMS) announced that 385 hospitals earned a 5‑star rating in the 2026 Overall Hospital Quality Star Ratings, up from 291 in 2025. The distribution shows most facilities clustered in the middle tiers, with...
SCOTUS Decides to Extend Telehealth Access to Abortion Care: FAQs on Preventive Care and Bodily Autonomy
On May 14, the Supreme Court extended an administrative stay that preserves mail‑order and telehealth prescriptions for the abortion pill mifepristone, pausing a Fifth Circuit ruling that sought to block such access in Louisiana. The decision keeps the FDA‑approved drug...
Contributor: Medication Adherence—A Lens Into How Well Health Care Is Working
Medication adherence is emerging as the most direct barometer of how well health‑care systems serve members. When patients consistently take prescribed drugs, chronic conditions stabilize, costly complications drop, and health‑plan star‑ratings improve. Conversely, gaps in adherence expose breakdowns in provider...
Organon to Present New Research on Access and Value at ISPOR 2026
Organon (NYSE: OGN) will showcase eight peer‑reviewed abstracts at ISPOR 2026, the premier health‑economics conference in Philadelphia. The presentations span cost‑effectiveness and budget‑impact analyses for its women’s health implant NEXPLANON in Brazil, the atopic dermatitis cream VTAMA from a U.S. Medicaid...
_on_a_T-cell_is_binding_to_a_molecule_on_a_cancer_-_Alpha_Tauri_3D_Graphics_M1_dc8762afeaee4937ad644739f274c7a5-620x480.jpg)
New Guidelines for Identifying and Treating High-Risk IEC-HS Patients
CAR‑T therapy’s success is tempered by the rare immune‑effector cell‑associated hemophagocytic lymphohistiocytosis‑like syndrome (IEC‑HS). A new review in the Chinese Medical Journal details how IEC‑HS differs from severe cytokine release syndrome, noting a later onset around two weeks post‑infusion and...
Aardvark's Next Move After Clinical Hold; Alumis' Verdict on Acelyrin Asset
Aardvark Therapeutics announced that the FDA clinical hold on its rare‑disease HERO and OLE studies has been lifted, allowing the company to unblind the trial data. The unblinding will provide critical efficacy and safety readouts for the targeted condition. In...
Combining Data Can Identify High-Risk Cohorts for SDOH Initiatives
MedeAnalytics COO Saleem Tahir urges providers and payers to merge claims, clinical and social risk data to better target social determinants of health (SDOH) initiatives. By integrating these datasets, organizations can pinpoint high‑risk cohorts and allocate resources more precisely. The...
Healthcare AI Evaluation Frameworks: Moving Beyond Accuracy to Safety and Fairness
Healthcare AI is now embedded in 71% of US hospitals, yet many deployments fall short of promised gains. Most evaluations rely on accuracy metrics such as AUROC, ignoring safety, fairness, calibration, and workflow compatibility. Studies show over 95% of AI...
Sun Pharma Recalls Cancer Drug After Finding Glass Particles in some Vials
Sun Pharma is recalling 675 vials of its doxorubicin hydrochloride liposome chemotherapy drug in the United States after glass particles were found in the vials. The batch, manufactured at Sun's Halol, India facility, has not generated any adverse event reports,...
Private Voice AI in Healthcare: How to Capture Critical Conversations Without Letting Patient Data Leave the Building
Healthcare’s strict HIPAA rules prevent most providers from using cloud‑based AI notetakers, leaving only 21% of physicians with AI assistance. On‑premises voice AI deploys generative models inside hospital infrastructure, ensuring audio and transcripts never leave the building. This local processing...
Strengthening Medicare Advantage to Better Serve Today’s Seniors
Medicare Advantage (MA) enrollment is expected to rise from 35 million today to about 45 million by 2030, covering roughly one‑tenth of the U.S. population. Hospital leaders have urged stronger federal oversight after many MA plans delay or deny care, especially through...
Medikit Co Ltd Posts 5.4% Revenue Rise to ¥23.8 Bn, Profit of ¥3.0 Bn
Medikit Co Ltd disclosed a 5.4% jump in full‑year revenue to ¥23.781 bn (≈$153 m) and a profit of ¥3.006 bn (≈$19 m) for the fiscal year ending March 2026. The results underscore expanding adoption of its specialized medical kits in Japan’s health‑tech market.
Successful Hookworm Vaccine Trials Aim for Global Low‑Cost Scale
No need to bother our friend @grok the answer is yes, our vaccine group was funded by Gates Foundation for a hookworm anemia vaccine although the funding stopped a decade ago. But we just published in @TheLancetInfDis that the vaccine...
Faster Biological Aging Linked to Higher Cardiovascular Risk
Association between accelerated biological aging and major adverse cardiovascular events in patients with stable coronary artery disease https://t.co/KOy0EElZQe
Trump Administration’s $1 Trillion Medicaid Cuts Threaten Care for Disabled Adults’ Families
The Trump administration’s Medicaid reform plan, projected to cut $1 trillion over the next decade, threatens to eliminate paid family‑caregiver programs that support disabled adults. States like Maryland have already slashed $126 million, cutting caregiver wages by $18,000 per family, while Vice...
Antibody‑Drug Conjugates Surge in Cancer Clinical Research
The progress and intensity of clinical research efforts with antibody-drug conjugates vs cancer is remarkable A new @CellCellPress review https://t.co/bkaJ2OOt63
LLMs in EHRs Enable Earlier Cancer Risk Detection
We could pick up risk of cancer and detect it much earlier if we applied LLMs to electronic health records, as shown in this @AllofUsResearch study https://t.co/VBFxeOWZAz
Cogent Biosciences Targets Transformational 2026 with Bezuclastinib
Cogent Biosciences Inc. says its lead drug candidate Bezuclastinib will hit several regulatory and clinical checkpoints in 2026, positioning the firm for a pivotal year. The tyrosine‑kinase inhibitor targets the KIT D816V mutation that drives most gastrointestinal stromal tumors and...
Why Corporate Medicine Fails Every Physician-Patient
Ronald L. Lindsay, a developmental‑behavioral pediatrician, argues that corporate medicine systematically fails physician‑patients because billing imperatives eclipse clinical judgment. He describes how his insider knowledge forces him to micromanage his own care, ration physical‑therapy visits, and anticipate delays that others...
Philippine HMOs Post 41% Net Income Jump in Q1
Philippine health maintenance organizations (HMOs) posted a 41% jump in first‑quarter net income, reaching ₱818.7 million (about $14.7 million) versus ₱579.4 million a year earlier. Membership fees surged 19.7% to ₱26.83 billion ($483 million), outpacing claim payouts that grew 14% to ₱20.15 billion ($363 million). Total assets...
Former Ovid CEO Dr. Jeremy Levin’s Rallying Cry for Biotech
Former Ovid Therapeutics CEO Dr. Jeremy Levin is launching a new book, *Biotech in the Balance*, slated for May 19. The book outlines a roadmap for positioning biotech as a strategic U.S. industry, calling for tax incentives, stronger patient engagement, and...
Innovation in Community Oncology: Moving Faster, Close to Home
The 2026 Community Oncology Alliance conference highlighted how community practices are rapidly integrating advanced therapies such as CAR‑T and bispecific antibodies, supported by AI-driven workflow tools and new real‑world data standards. Speakers emphasized the need for expanded infusion capacity, symptom...
Malaysia OKs Korean AI for Sepsis Prediction and More AI Briefs
South Korean AI firm AITRICS secured Class C medical‑device approval in Malaysia for its VitalCare sepsis‑prediction software, marking its sixth regulatory clearance after Indonesia. In Thailand, Taiwan’s Acer Medical teamed with local partners to deploy an integrated AI‑assisted eye‑screening and...